AWM
AXSM icon

Abound Wealth Management’s Axsome Therapeutics AXSM Stock Holding History

Abound Wealth Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9
Closed -$1.52K – 1386
2026
Q1 		$1.52K Buy
+9
New +$1.55K ﹤0.01% 947

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Abound Wealth Management's AXSM Position: Q2 2026 in Review

Abound Wealth Management sold out of Axsome Therapeutics (AXSM) in Q2 2026, closing a stake of 9 shares — an estimated $1.52K sold.

Abound Wealth Management first reported a position in AXSM in Q1 2026 and held it in 1 quarter. The position peaked at $1.52K in Q1 2026. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Abound Wealth Management reported no remaining Axsome Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Abound Wealth Management sold 9 Axsome Therapeutics shares in Q2 2026, an estimated $1.52K.
  • Abound Wealth Management first reported a position in Axsome Therapeutics in Q1 2026 and held it in 1 quarter.
  • Abound Wealth Management's Axsome Therapeutics position peaked at $1.52K in Q1 2026.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.